Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag
Intest Res. 2019;17(3):340-348.   Published online 2019 May 31     DOI: https://doi.org/10.5217/ir.2019.00012
Citations to this article as recorded by Crossref logo
Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease-results from the ENEIDA registry. Authors' reply
Marisa Iborra, Belén Beltrán, Pilar Nos
Alimentary Pharmacology & Therapeutics.2019; 50(5): 600.     CrossRef